BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

33 related articles for article (PubMed ID: 11848470)

  • 21. Antiangiogenic and antitumor effects of a protein kinase C beta inhibitor in human hepatocellular and gastric cancer xenografts.
    Teicher BA; Menon K; Alvarez E; Liu P; Shih C; Faul MM
    In Vivo; 2001; 15(3):185-93. PubMed ID: 11491013
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human breast cancer and ovarian cancer xenografts.
    Teicher BA; Menon K; Alvarez E; Shih C; Faul MM
    Invest New Drugs; 2002 Aug; 20(3):241-51. PubMed ID: 12201487
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in murine lewis lung carcinoma and human Calu-6 non-small-cell lung carcinoma xenografts.
    Teicher BA; Menon K; Alvarez E; Galbreath E; Shih C; Faul MM
    Cancer Chemother Pharmacol; 2001 Dec; 48(6):473-80. PubMed ID: 11800028
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human T98G glioblastoma multiforme xenografts.
    Teicher BA; Menon K; Alvarez E; Galbreath E; Shih C; Faul M
    Clin Cancer Res; 2001 Mar; 7(3):634-40. PubMed ID: 11297259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiangiogenic effects of a protein kinase Cbeta-selective small molecule.
    Teicher BA; Alvarez E; Menon K; Esterman MA; Considine E; Shih C; Faul MM
    Cancer Chemother Pharmacol; 2002 Jan; 49(1):69-77. PubMed ID: 11855754
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human HT-29 colon carcinoma and human CaKi1 renal cell carcinoma xenografts.
    Teicher BA; Menon K; Alvarez E; Galbreath E; Shih C; Faul MM
    Anticancer Res; 2001; 21(5):3175-84. PubMed ID: 11848470
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination therapy for renal cell cancer: what are possible options?
    Santos N; Wenger JB; Havre P; Liu Y; Dagan R; Imanirad I; Ivey AM; Zlotecki RA; Algood CB; Gilbert SM; Allegra CJ; Okunieff P; Vieweg J; Dang NH; Luesch H; Dang LH
    Oncology; 2011; 81(3-4):220-9. PubMed ID: 22085914
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting angiogenesis in metastatic renal cell carcinoma.
    Canino C; Perrone L; Bosco E; Saltalamacchia G; Mosca A; Rizzo M; Porta C
    Expert Rev Anticancer Ther; 2019 Mar; 19(3):245-257. PubMed ID: 30678509
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Basis for effective combination cancer chemotherapy with antimetabolites.
    Peters GJ; van der Wilt CL; van Moorsel CJ; Kroep JR; Bergman AM; Ackland SP
    Pharmacol Ther; 2000; 87(2-3):227-53. PubMed ID: 11008002
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 31.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 32.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 33.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 2.